Journal
CHEMISTRY-AN ASIAN JOURNAL
Volume 13, Issue 22, Pages 3333-3340Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/asia.201800149
Keywords
bioinorganic chemistry; cancer; drug delivery; nanostructures
Categories
Funding
- National Key Research and Development Program of China [2016YFA0201400]
- Beijing Natural Science Foundation-Haidian Original Innovation Joint Fund [17L20170]
- National Project for Research and Development of Major Scientific Instruments [81727803]
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China [81421004]
Ask authors/readers for more resources
The application of nanotechnology in the treatment of tumors has boomed owing to the vigorous development in cancer nanomedicine. Despite the great success achieved in this field, nanomedicine has not realized its full potential owing to a delivery barrier, the mononuclear phagocytic system (MPS), which cuts off more than 95 % of the administrated nanoparticles. This results in an extremely low drug-delivery efficacy to the tumor and leads to poor therapeutic outcomes. Moreover, the injection of excess nanoparticles also raises toxicity concerns induced by the accumulation of nanomaterials in organs, such as the liver and spleen. Therefore, a reduction in the uptake of nanomedicines by the MPS is vital to enhance the cancer therapeutic effect and decrease side effects. In this critical review, we will summarize the new strategies to reduce nanoparticle uptake by the MPS based on current knowledge of the bio-nano interaction. Further directions will also be highlighted for the development of cancer nanomedicine with a lower off-target rate and better therapeutic outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available